Ulcerative colitis (UC), a chronic recurrent inflammation of the colonic mucosa, has become a global emergency. With the restricted response and significant side effects of traditional drugs, a search for alternatives is mandatory. The current study aimed to evaluate the therapeutic effects of hydatid cyst fluid (HCF) and laminated layer (HLL) derived crude extract of E. granulosus, combined with the standard medication sulfasalazine (SLZ), for treating acetic acid-induced colitis. Mice were divided into 7 groups. A colitis model using acetic acid (150 μl of 5% con.) intrarectally was induced. On the 8th day following colitis induction, the mice were sacrificed. We assessed the severity of colitis using survival rate, disease activity index, colon weight/length ratio, colon weight/bodyweight ratio, and gross and histopathological score of colon damage. Immunohistochemistry for Foxp3 T-reg expression in colonic tissues was done. The levels of inflammatory cytokines tumor necrosis factor-α and IL-10, oxidative stress marker malondialdehyde, and total antioxidant capacity in serum samples were assessed. Groups treated with a combination of SLZ+HCF and SLZ+HLL revealed a statistically significant improvement compared to the colitis group by improving disease activity index, colon weight/length ratio and colon weight/bodyweight ratio, and gross and histopathological colon damage scores. Additionally, there was a significant rise in IL-4, TAC, and Foxp3+ Treg cell expression and decreased TNF-α and MDA expression. E. granulosus-derived HCF and HLL potentiate the protective effect of SLZ by increasing anti-inflammatory and antioxidant properties against murine colitis, suggesting the potential for novel therapeutic approaches.